
Regenlab USA Inc.
RGNAFiledRegenlab USA Inc. · Nasdaq · Research source · S-1 · 2026-09-25 · Latest filing · S-1/A · 2026-10-27 SEC ↗
Preliminary S-1 leaves core IPO terms incomplete despite established regenerative-medicine operations.
As of the September 25, 2026 S-1, RegenLab’s IPO price, share count and proceeds remain placeholders, while Nasdaq listing is unapproved.
- Business and development direction
Regenlab USA Inc.
Current business Future development
Key risks
Risk 1
Failure to obtain or maintain CE-MDR, FDA 510(k), PMA or other approvals could delay or prevent commercialization.
Risk 2
Commercialization depends on reimbursement, healthcare-professional relationships, sales-force development and distributors.
Risk 3
The company reports operating losses, negative operating cash flow, substantial indebtedness, working-capital deficit and a going-concern reference.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Source-linked structured inputs are not yet available. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | StoneX Financial Inc. |
IPO CAPITAL QUALITY
Basis and evidence
S-1 · 2026-09-25
As of the September 25, 2026 S-1, RegenLab’s IPO price, share count and proceeds remain placeholders, while Nasdaq listing is unapproved.
Offering structure
Source and calculation
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Pre-offer shares | 6,238,266 | — |
Basis and evidence ↗
outstanding before offering
Reported inputs; each row retains its own source basis.
Share-count comparison
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source ↗IPO valuation scenario simulator
Source inputs required
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-25
Relationship filters
Select for details · Regenlab USA Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Antonino TurziEconomic ownership · Antonino Turzi | — | 98.64%Economic | — | beneficial ownership before offering |
| Antonino TurziBeneficial shares | 6,153,426 | — | — | Shares of CommonBeneficially StockOwned |
| Dr. Daphne Metzger, PhDBeneficial shares | 24,329 | — | — | Shares of CommonBeneficially StockOwned |
| All directors and executive officers as a group (8 persons)Beneficial shares | 6,177,755 | — | — | Shares of CommonBeneficially StockOwned |
| Antonino TurziBeneficial ownership | — | 98.64%Beneficial | — | Percent of CommonStock BeneficiallyOwned BeforeOffering(1) |
| All directors and executive officers as a group (8 persons)Beneficial ownership | — | 99.01%Beneficial | — | Percent of CommonStock BeneficiallyOwned BeforeOffering(1) |
| Mr. Antonino Turzi, our principal stockholder, currentlyVoting power | — | — | approximately 98.64%Voting power | Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock (based on shares of common stock outstanding as of September 21, 2026) and will control approximately [___]% of the combined voting power of our capital stock; not an additive ownership partition |
| Antonino Turzi, our principal stockholderVoting power | — | — | approximately 98.5%Voting power | Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock (based on shares of common stock outstanding as of December 31, 2025) and will control approximately [___]% of the combined voting power of our capital stock; not an additive ownership partition |
| our FounderOwnership as disclosed | — | >50%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding shares of common stock, which will cause us to be deemed a “controlled company” under the rules of Nasdaq; not an additive ownership partition |
| our FounderVoting power | — | — | approximately 98.64%Voting power | Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering; not an additive ownership partition |
| Mr. TurziOwnership as disclosed | — | >50%Beneficial | — | Source statement; >; source predicate: owns; primary source clause; full source conditions retained; source scope: of our outstanding shares (and will continue to own more than; not an additive ownership partition |
Source and calculation ↗
beneficial ownership before offering
beneficial ownership before offering
Exact source ownership column: Shares of CommonBeneficially StockOwned; holders may overlap; not an additive partition
Raw source column: Shares of CommonBeneficially StockOwned; source holder: Antonino Turzi
Exact source ownership column: Shares of CommonBeneficially StockOwned; holders may overlap; not an additive partition
Raw source column: Shares of CommonBeneficially StockOwned; source holder: Dr. Daphne Metzger, PhD
Exact source ownership column: Shares of CommonBeneficially StockOwned; holders may overlap; not an additive partition
Raw source column: Shares of CommonBeneficially StockOwned; source holder: All directors and executive officers as a group (8 persons)
Exact source ownership column: Percent of CommonStock BeneficiallyOwned BeforeOffering(1); holders may overlap; not an additive partition
Raw source column: Percent of CommonStock BeneficiallyOwned BeforeOffering(1); source holder: Antonino Turzi
Exact source ownership column: Percent of CommonStock BeneficiallyOwned BeforeOffering(1); holders may overlap; not an additive partition
Raw source column: Percent of CommonStock BeneficiallyOwned BeforeOffering(1); source holder: All directors and executive officers as a group (8 persons)
Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock (based on shares of common stock outstanding as of September 21, 2026) and will control approximately [___]% of the combined voting power of our capital stock; not an additive ownership partition
Mr. Antonino Turzi, our principal stockholder, currently controls approximately 98.64% of the voting power of our capital stock (based on shares of common stock outstanding as of September 21, 2026) and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering, and we are therefore a “controlled company” as defined under Nasdaq Marketplace Rules. We do not intend to rely on the controlled company exemptions provided under Nasdaq Marketplace Rules.
Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock (based on shares of common stock outstanding as of December 31, 2025) and will control approximately [___]% of the combined voting power of our capital stock; not an additive ownership partition
Antonino Turzi, our principal stockholder, controls approximately 98.5% of the voting power of our capital stock (based on shares of common stock outstanding as of December 31, 2025) and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering, and we are therefore a “controlled company” as defined under Nasdaq Marketplace Rules. We do not intend to rely on the controlled company exemptions provided under Nasdaq Marketplace Rules.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding shares of common stock, which will cause us to be deemed a “controlled company” under the rules of Nasdaq; not an additive ownership partition
Antonino Turzi, our Founder, Chairman and CEO, beneficially owns greater than 50% of our outstanding shares of common stock, which will cause us to be deemed a “controlled company” under the rules of Nasdaq.
Source statement; approximately ; source predicate: controls; primary source clause; full source conditions retained; source scope: of the voting power of our capital stock and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering; not an additive ownership partition
Antonino Turzi, our Founder, Chairman and CEO, currently controls approximately 98.64% of the voting power of our capital stock and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering. As a result, Mr. Turzi owns more than 50% of our outstanding shares (and will continue to own more than 50% of our outstanding shares upon consummation of the offering), and as such, we are a “controlled company” under the rules of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a “controlled company” and, as such, can elect to be exempt from certain corporate governance requirements, including requirements that:
Source statement; >; source predicate: owns; primary source clause; full source conditions retained; source scope: of our outstanding shares (and will continue to own more than; not an additive ownership partition
Antonino Turzi, our Founder, Chairman and CEO, currently controls approximately 98.64% of the voting power of our capital stock and will control approximately [___]% of the combined voting power of our capital stock upon completion of this offering. As a result, Mr. Turzi owns more than 50% of our outstanding shares (and will continue to own more than 50% of our outstanding shares upon consummation of the offering), and as such, we are a “controlled company” under the rules of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a “controlled company” and, as such, can elect to be exempt from certain corporate governance requirements, including requirements that:
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Antonino TurziDisclosed holder | — | 98.64% | — | 2026-09-25Antonino Turzi remains the dominant holder and voting controller; post-offering percentages are blank.S-1 ↗ |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Conditional lock-up duration
| Measure | Reported value |
|---|---|
| Conditional lock-up duration · executive officers and directorsfollowing closing date; subject to Representative consent | 180 days |
| Conditional lock-up duration · all holders of common stock and exercisable or convertible securitiesfollowing effective date of registration statement; subject to Representative consent | 180 days |
Source and calculation
following closing date; subject to Representative consent
The Offering ↗following effective date of registration statement; subject to Representative consent
The Offering ↗Source lock-up conditions
Literal day restriction; anchor not separately resolved; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our executive officers and directors | 180 days |
| Our executive officers and directors | 180 days |
| the warrants | 180 days |
| our executive officers and directors and holders of all of our common stock | 180 days |
Source and calculation
Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the closing date of this initial public offering without the prior written consent of the Representative. Any other holders of outstanding shares of our common stock (and all holders of securities exercisable for or convertible into shares of common stock) have also agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the effective date of the registration statement for this offering without the prior written consent of the representative. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC table 102 row 15; source 265974:277956; SHA256 ed269f84a488be3167ed4f84cc4f7b90776cda442d6c71f0583e9e65ad847452 ↗Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the closing date of this initial public offering without the prior written consent of the Representative. Any other holders of outstanding shares of our common stock (and all holders of securities exercisable for or convertible into shares of common stock) have also agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the effective date of the registration statement for this offering without the prior written consent of the representative. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 275318:276256; SHA256 a7ed7e274e2192072f379333cf085fa9c608e462c5f89dd763c01cdbb1c78f30 ↗The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days following the commencement of sales of the securities issued in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain cases. The sole demand registration right provided will not be greater than five years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration rights provided will not be greater than seven years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the Representative’s Warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 1842579:1844530; SHA256 9ff5cc592c7480484783e3ec9c286222ed6a00f74b6e0e9a5fd9f6dd2cf2fe51 ↗Pursuant to “lock-up” agreements, we, and our executive officers and directors and holders of all of our common stock, have agreed, without the prior written consent of the Representative, not to, directly or indirectly, offer to sell, sell, pledge, or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the closing date of this offering.
SEC lock-up paragraph; source 1845027:1846270; SHA256 d07068e929e05af3d33d1618ec24f0c6ba48512d44dc1f6bc5599d3e0f7f87ef ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our executive officers and directors | 180 days | Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the closing date of this initial public offering without the prior written consent of the Representative. Any other holders of outstanding shares of our common stock (and all holders of securities exercisable for or convertible into shares of common stock) have also agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the effective date of the registration statement for this offering without the prior written consent of the representative. For additional information regarding our arrangement with the underwriters, please see “Underwriting.” |
| the warrants | 180 days | The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days following the commencement of sales of the securities issued in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain cases. The sole demand registration right provided will not be greater than five years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration rights provided will not be greater than seven years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the Representative’s Warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. |
| our executive officers and directors and holders of all of our common stock | 180 days | Pursuant to “lock-up” agreements, we, and our executive officers and directors and holders of all of our common stock, have agreed, without the prior written consent of the Representative, not to, directly or indirectly, offer to sell, sell, pledge, or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the closing date of this offering. |
Basis and evidence
Our executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the closing date of this initial public offering without the prior written consent of the Representative. Any other holders of outstanding shares of our common stock (and all holders of securities exercisable for or convertible into shares of common stock) have also agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for 180 days following the effective date of the registration statement for this offering without the prior written consent of the representative. For additional information regarding our arrangement with the underwriters, please see “Underwriting.”
SEC lock-up paragraph; source 275318:276256; SHA256 a7ed7e274e2192072f379333cf085fa9c608e462c5f89dd763c01cdbb1c78f30 ↗The Representative’s Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days following the commencement of sales of the securities issued in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain cases. The sole demand registration right provided will not be greater than five years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration rights provided will not be greater than seven years from the commencement of sales of the securities issued in this offering in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the Representative’s Warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.
SEC lock-up paragraph; source 1842579:1844530; SHA256 9ff5cc592c7480484783e3ec9c286222ed6a00f74b6e0e9a5fd9f6dd2cf2fe51 ↗Pursuant to “lock-up” agreements, we, and our executive officers and directors and holders of all of our common stock, have agreed, without the prior written consent of the Representative, not to, directly or indirectly, offer to sell, sell, pledge, or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of our securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the closing date of this offering.
SEC lock-up paragraph; source 1845027:1846270; SHA256 d07068e929e05af3d33d1618ec24f0c6ba48512d44dc1f6bc5599d3e0f7f87ef ↗Financial quality
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2026-06-30 · Consolidated · Unaudited | $4,826,000 |
| Cash and cash equivalents2025-12-31 · Consolidated · Unaudited | $1,846,000 |
| Current assets2026-06-30 · Consolidated · Unaudited | $22,342,000 |
| Current assets2025-12-31 · Consolidated · Unaudited | $18,874,000 |
| Total assets2026-06-30 · Consolidated · Unaudited | $56,494,000 |
| Total assets2025-12-31 · Consolidated · Unaudited | $52,974,000 |
| Current liabilities2026-06-30 · Consolidated · Unaudited | $35,146,000 |
| Current liabilities2025-12-31 · Consolidated · Unaudited | $30,441,000 |
| Total liabilities2026-06-30 · Consolidated · Unaudited | $66,247,000 |
| Total liabilities2025-12-31 · Consolidated · Unaudited | $62,593,000 |
| Total equity / (deficit)2026-06-30 · Consolidated · Unaudited | ($9,753,000) |
| Total equity / (deficit)2025-12-31 · Consolidated · Unaudited | ($9,619,000) |
| General and administrative expenses6M ended 2026-06-30 · Consolidated · Unaudited | $5,831,000 |
| General and administrative expenses6M ended 2025-06-30 · Consolidated · Unaudited | $5,792,000 |
| Operating cash flow6M ended 2026-06-30 · Consolidated · Unaudited | $5,039,000 |
| Operating cash flow6M ended 2025-06-30 · Consolidated · Unaudited | $406,000 |
| Cash and cash equivalents2025-12-31 · Consolidated | $1,846,000 |
| Cash and cash equivalents2024-12-31 · Consolidated · Restated | $958,000 |
| Current assets2025-12-31 · Consolidated | $18,874,000 |
| Current assets2024-12-31 · Consolidated · Restated | $15,038,000 |
| Total assets2025-12-31 · Consolidated | $52,974,000 |
| Total assets2024-12-31 · Consolidated · Restated | $44,389,000 |
| Current liabilities2025-12-31 · Consolidated | $30,441,000 |
| Current liabilities2024-12-31 · Consolidated · Restated | $19,123,000 |
| Total liabilities2025-12-31 · Consolidated | $62,593,000 |
| Total liabilities2024-12-31 · Consolidated · Restated | $52,186,000 |
| Total equity / (deficit)2025-12-31 · Consolidated | ($9,619,000) |
| Total equity / (deficit)2024-12-31 · Consolidated · Restated | ($7,797,000) |
| General and administrative expensesFY2025 · Consolidated | $11,385,000 |
| General and administrative expensesFY2024 · Consolidated · Restated | $11,774,000 |
| Operating cash flowFY2025 · Consolidated | ($542) |
| Operating cash flowFY2024 · Consolidated · Restated | $4,434 |
Basis and evidence
Financial quality and runway
Financial quality and runway
The latest supplied period is the six months ended June 30, 2026; interim results are unaudited and not necessarily indicative of the full year.
EvidenceFinancial review 1Six-month 2026 net product sales were $29.318 million and net income was $0.071 million, versus $24.224 million sales and $0.032 million loss in the comparable 2025 period.
+
Six-month 2026 net product sales were $29.318 million and net income was $0.071 million, versus $24.224 million sales and $0.032 million loss in the comparable 2025 period.
EvidenceFinancial review 2Six-month 2026 operating cash flow was $5.039 million.
+
Six-month 2026 operating cash flow was $5.039 million.
EvidenceFinancial review 3For 2025, revenue was $49.170 million and net loss was $1.241 million; operating cash flow was negative $0.542 million.
+
For 2025, revenue was $49.170 million and net loss was $1.241 million; operating cash flow was negative $0.542 million.
EvidenceFinancial review 4The filing states substantial indebtedness, working-capital deficit and a going-concern reference; the latest interim cash and debt balances are not supplied.
+
The filing states substantial indebtedness, working-capital deficit and a going-concern reference; the latest interim cash and debt balances are not supplied.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
S-10001829126-26-010431 ↗
Loading filing history…
Failure to obtain or maintain CE-MDR, FDA 510(k), PMA or other approvals could delay or prevent commercialization.
- Evidence
- Risk Factors ↗
Commercialization depends on reimbursement, healthcare-professional relationships, sales-force development and distributors.
- Evidence
- Summary of Risk Factors ↗
The company reports operating losses, negative operating cash flow, substantial indebtedness, working-capital deficit and a going-concern reference.
- Evidence
- Summary of Risk Factors ↗
Turzi's continuing control may limit minority investors' ability to influence transactions, including a change of control.
- Evidence
- Summary of Risk Factors ↗